Linford Stillson, DO
Internal Medicine · Westbrook, MENPI 1710059902
Payments from drug & device makers
Across 549 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$1K
- Boehringer Ingelheim$810
- Lilly USA, LLC$659
- Amgen$637
- Pfizer$623
- plus $3K from 28 others
What the payments were for
- Food & beverage$10,60199%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 200 | $3,886 |
| AstraZeneca | 61 | $1,226 |
| Boehringer Ingelheim | 32 | $810 |
| Lilly USA, LLC | 31 | $659 |
| Amgen | 32 | $637 |
| Pfizer | 48 | $623 |
| GSK | 17 | $366 |
| Novo Nordisk | 17 | $298 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $280 |
| Teva Pharmaceuticals USA, Inc. | 11 | $219 |
| Merck | 10 | $165 |
| Corcept Therapeutics | 7 | $151 |
| Verona Pharma, Inc. | 7 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $137 |
| Lundbeck LLC | 5 | $129 |
| Johnson & Johnson | 5 | $111 |
| Amarin Pharma, Inc. | 5 | $86 |
| Biodelivery Sciences International, Inc. | 3 | $77 |
| Esperion Therapeutics, Inc. | 4 | $76 |
| Bayer | 3 | $75 |
| Sunovion Pharmaceuticals Inc. | 3 | $74 |
| Novartis | 3 | $71 |
| Kowa Pharmaceuticals America, Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Scilex Pharmaceuticals Inc. | 3 | $50 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Corium, LLC | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Abbott | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,655 in reported general payments places this provider in the 95th percentile of 445 internal medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $50,819 |
| JardianceEmpagliflozin | 21 | $26,350 |
| TrulicityDulaglutide | 11 | $18,467 |
| OxycontinOxycodone Hcl | 13 | $17,084 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $15,585 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $8,767 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 126 | $6,994 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $4,733 |
| Oxycodone Hcl | 79 | $2,995 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 11 | $2,305 |
| Sertraline Hcl | 31 | $2,003 |
| SynthroidLevothyroxine Sodium | 15 | $1,537 |
| Atorvastatin Calcium | 176 | $1,261 |
| Omega-3 Acid Ethyl Esters | 21 | $982 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $623 | $50,81957 claims |
| Boehringer IngelheimJardiance | $810 | $26,35021 claims |
| Lilly USA, LLCTrulicity | $659 | $18,46711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $280 | $8,76723 claims |
| GSKShingrix | $366 | $2,30511 claims |
| AbbVieSynthroid | $3,886 | $1,53715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 445 internal medicine providers in Maine.
Other internal medicine in Westbrook
- Elizabeth DennisWestbrook$17K
- Nananda ColPortland$1.4M
- Nathaniel JamesPortland$78K
- James ZeitlinPortland$52K
- Charles CathcartPortland$40K
- Debra Fuchs ErtmanPortland$38K
- Heidi DeblockPortland$27K
- Gene ChengAugusta$22K
- William ErvinPortland$16K
- Hassan AbouleishHoulton$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.